Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupIndolent LymphomasTransplantationDiseaseMantle Cell LymphomaStem Cell Transplantation, AutologousSubgroupICD10C83.1Z94.80MeSHTransplantation, AutologousSequenceTRIANGLEChemotherapyChemo-substanceChemo-substanceChemo-substanceChemo-substanceNo. Substances RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleCytarabineDexamethasoneFosaprepitantGranisetronMelphalanValaciclovirSupportive substanceBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleCytarabineDexamethasoneFosaprepitantGranisetronMelphalanValaciclovirSupportive substanceBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleCytarabineDexamethasoneFosaprepitantGranisetronMelphalanValaciclovirSupportive substanceBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleCytarabineDexamethasoneFosaprepitantGranisetronMelphalanValaciclovirNo. Substances9Protocol classificationTherapy classificationalternativeIntensityHochdosis, bei autologer SZTTherapy indicationseveral possibleTherapy phaseautologous stem cell transplantationTherapy intentioncurativeRisksEmetogenicity (MASCC/ESMO) only studiesPublicationAuthorDreyling MDiseaseMantelzelllymphom, Stadium II-IV, 18-65 J., transplantfähig, Erstlinie, ECOG 0-2OriginLMU University Hospital, Munich, Germany, TRIANGLE StudyProtokolle in Überarbeitung 1 protocol foundTHAM - Cytarabine 1500 / Melphalan 140 / TBI, Mantle Cell Lymphoma, Autologous Stem Cell Transplantation (PID3165 V1.1)
